Subject(s)
Adenocarcinoma, Mucinous/metabolism , Cystadenocarcinoma/metabolism , Ovarian Neoplasms/metabolism , Receptors, Steroid/analysis , Centrifugation, Density Gradient , Cytosol/analysis , Female , Humans , Receptors, Androgen/analysis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysisABSTRACT
In the brain tumors hormone dependency has long been suggested from the evidence that meningiomas and neurinomas are frequently seen in female and that they enlarge during pregnancy presumably as a result of hormonal change. Recently the presence of estrogen receptor (ER) in meningiomas, neurinomas and pituitary adenomas were documented in some preliminary reports. In this report we estimated the ER in the tissue of 15 patients with meningiomas (13 females and 2 males) and 5 with neurinomas (2 females and 3, males). The estrogen receptor level was determined by Scatchard analysis. The results were obtained as follows: In meningiomas, 80% (4/5) of premenopausal females, 25% (2/8) of postmenopausal females and 0% (0/2) of males had receptor activity. Maximal binding sites (Bm; fmol/mg cytosol protein) and dissociation constant (Kd; x 10(-10)M) are as follows: Bm=20.8+/-12.2 (premenopause; n=4) or 22.8 (postmenopause; n=2) and Kd=2.8+/-0.7 (premenopause) or 6.9 (postmenopause). In neurinoma, 33% (1/3) of males and 0% (0/2) of females had receptor activity. Bm and Kd are as follows: Bm=25.0 and Kd=2.3. The ER detectable rate in meningiomas was much higher in premenopausal females. There was a suggestion that some brain tumors are responsible to estrogen via cellular estrogen receptor.
Subject(s)
Brain Neoplasms/analysis , Meningeal Neoplasms/analysis , Meningioma/analysis , Neurilemmoma/analysis , Receptors, Estrogen/analysis , Adult , Aged , Female , Humans , Male , Menopause , Middle AgedABSTRACT
In order to evaluate the efficacy and safety of pivmecillinam (melysin tablet, PMPC), PMPC was administered to 78 chronic UTI cases in the field of obstetrics and gynecology (posthysterectomy infection, chronic cystitis, chronic pyelonephritis and etc.). In principle, daily 400 mg of PMPC was administered for 2 weeks. (1) Overall clinical efficacy judged by doctor was evaluated in 78 cases and the result was; excellent in 17, good in 37, fair in 10, poor in 13 and unknown in 1 case with the effectiveness rate of 69.2%. (2) Overall clinical efficacy judged by 'criteria for clinical evaluation in complicated UTI' recommended by UTI study member was evaluated in 54 cases and the result was; excellent in 15, good in 20 and poor in 19 cases with the overall efficacy rate of 64.8%, the result of which was similar to that of doctor's judgement. (3) Efficacy on pyuria was evaluated in 72 cases and it was cleared in 27, decreased in 25, unchanged in 20 and unknown in 6 cases. Efficacy on bacteriuria was evaluated in 72 cases and it was eliminated in 44, decreased in 9, replaced in 8, unchanged in 8 and unknown in 9 cases. (4) Side effect, considered by doctors to be caused by PMPC administration, was noticed in 3 out of 78 cases (3.8%), all of which was mild gastrointestinal disturbance and the administration of PMPC was continued. Abnormal change of laboratory finding considered by doctors to be caused by PMPC administration was noticed in 1 out of 78 cases, which was slight elevation of GOT and GPT values. It is therefore considered that PMPC appear to be useful drug for the maintenance therapy of chronic UTI in the field of obstetrics and gynecology.
